Stopping beta blockers after heart bypass surgery
BEta Blocker dEprescription Following Coronary Artery Bypass Graft sURGERy: Feasibility and Safety Pilot (BEEFBURGER Trial)
This study is testing whether stopping beta-blockers after heart bypass surgery is safe and beneficial for patients with good heart function.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Saskatchewan Academic / other |
| Locations | 1 site (Saskatoon, Saskatchewan) |
| Trial ID | NCT04788186 on ClinicalTrials.gov |
What this trial studies
This trial evaluates the effects of continuing versus stopping beta-blocker therapy in patients who have undergone isolated coronary artery bypass graft (CABG) surgery. It is a randomized, open-label study that aims to determine the feasibility of de-prescribing beta-blockers 6-8 weeks post-surgery in patients with preserved heart function. The study will assess various health outcomes, including mortality and cardiovascular events, over a 3-year follow-up period. Additionally, patient-reported quality of life and angina scores will be measured to evaluate the impact of the intervention.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have undergone isolated CABG and are on beta-blocker therapy with preserved left ventricular function.
Not a fit: Patients with a history of heart failure, atrial fibrillation, or other compelling indications for beta-blocker therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help clarify the long-term role of beta-blockers in patients after CABG, potentially leading to more personalized and effective treatment strategies.
How similar studies have performed: While the specific approach of beta-blocker de-prescription post-CABG is novel, similar studies have explored the management of beta-blockers in various cardiac conditions with varying results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years treated with index isolated CABG * Able to consent to study * On beta blocker therapy at the 6-8week visit * LV systolic function (≥45% assessed within 6months of CABG date) Exclusion Criteria: * Prior heart failure with reduced ejection fraction (LVEF \<45%) * Pre- or peri-operative atrial fibrillation or flutter * Peri-CABG stroke * Unable to follow-up
Where this trial is running
Saskatoon, Saskatchewan
- Royal University Hospital — Saskatoon, Saskatchewan, Canada (Recruiting)
Study contacts
- Study coordinator: Jay Shavadia, MD
- Email: jss372@usask.ca
- Phone: 3069862260
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.